This is an excerpt from Eagle Point Capital’s Fall 2023 letter to clients. Every six months, EPC writes to clients to explain what they own and why they own it. The portfolio-specific portion of each letter is for clients and prospective clients only. If you’d like to invest with EPC, please
The skeptic in me would say that even if GLP-1 and GLP-2 inhibitors were widely available I wouldn't necessarily say this would solve the issue of obesity if it also doesn't correspond with long-term lifestyle changes. The weight regain statistics post weight-loss are quite sobering.
I agree Adam. Right now GLP-1s are made to seem like magic bullets with only upsides and no downsides. That's not typically how anything, especially pharmaceuticals, work. Time will tell and it will be interesting to monitor.
The skeptic in me would say that even if GLP-1 and GLP-2 inhibitors were widely available I wouldn't necessarily say this would solve the issue of obesity if it also doesn't correspond with long-term lifestyle changes. The weight regain statistics post weight-loss are quite sobering.
https://www.michiganmedicine.org/health-lab/weighing-facts-tough-truth-about-weight-loss
I agree Adam. Right now GLP-1s are made to seem like magic bullets with only upsides and no downsides. That's not typically how anything, especially pharmaceuticals, work. Time will tell and it will be interesting to monitor.